Right now, most of the news coming out of the psychedelic world is not about approvals. It's about discovery. Scientists are publishing paper after paper explaining how these drugs actually work in the brain. That's the loud signal today. The quieter signal is what isn't happening: the government has made no move to relax its rules. The DEA — the agency that decides how tightly a drug is controlled — is still treating psilocybin and MDMA as Schedule I, its most restricted category, the one for drugs it considers to have no accepted medical use. Meanwhile, the FDA, the agency that approves medicines, is expected to demand at least one more large, careful MDMA study before it says yes. The main worry is that in these trials people can often tell whether they got the real drug or a fake pill, which makes results harder to trust.
Beneath all of this is a simple truth: the roots are growing faster than the fence around them. Understanding is racing ahead of permission. The best guess from today's signals is that no big legal change to psilocybin or MDMA happens before 2028. But there's a softer, warmer current moving too. Lawmakers from both political parties are quietly lining up behind veterans. A pilot program at the VA — the government's health system for former soldiers — or a small law giving veterans access could arrive within a year. That would be the crack in the door. The highest realistic path here isn't a sudden flood. It's a slow, honest build: deeper science, then careful trials, then a narrow first door opened for the people hurting most.
For the human beings inside this story, the feeling right now is a mix of hope and tiredness. A veteran who has tried every approved treatment for the nightmares and can't sleep hears "not before 2028" and feels the weight of more waiting. A person with depression that no pill has touched reads about brain research and wonders when research turns into a treatment they can actually walk in and receive. That ache is real, and it deserves honesty, not sugar. But here is what's genuinely possible: every study published today is a brick laid under a future that can't be knocked down. When access finally comes — and the signals say it will come — it will be built on something solid, so it lasts. The slowness is painful. It is also what makes the eventual door real instead of a promise that collapses.
What is being called in cannot be called back. The currents forming in legislation, in research, in culture — OOTW reads them daily, so you don't have to navigate them alone.
The current is already moving. You are already in it.
75%
Psilocybin and MDMA stay federally illegal until at least 2028
The DEA (the US agency that classifies drugs) keeps psilocybin and MDMA in the most restricted category, meaning no legal use outside approved research. This matters because even if the FDA (the US drug regulator) approves a psychedelic medicine, doctors still can't prescribe it without the DEA agreeing to loosen restrictions. That agreement won't happen quickly.
→ The federal government will keep these drugs in the most restricted category until at least 2028, no matter what state laws or research says.
Resolves: 2028-01-01 · USA
REGULATORY
the precise call ▾
No federal descheduling of psilocybin or MDMA before 2028; DEA maintains Schedule I posture.. DEA concurrence is required and won't come without airtight NDAs and diversion controls. I have to justify every step to devastated communities. The bar stays high.
74%
FDA will require another MDMA study before approving it as a medicine
The FDA rejected MDMA-assisted therapy in 2024 partly because participants in trials could usually tell whether they got the real drug — which could skew results. The FDA wants a new study that accounts for this problem before it will approve MDMA as a treatment. This delays relief for people with PTSD (post-traumatic stress disorder) who were hoping for a legal option soon.
→ The FDA wants a better-designed study before it will approve MDMA as medicine, pushing any approval well into the future.
Resolves: 2027-06-30 · USA
REGULATORY
the precise call ▾
FDA will demand at least one confirmatory MDMA trial addressing functional unblinding before any approval.. Unblinding and expectancy bias remain unresolved. My duty is patient protection over urgency, and no advisory committee will overlook methodology flaws despite the suffering.
73%
Psilocybin and MDMA remain federally illegal through at least 2028
Multiple government insiders — including drug enforcement officers, lawmakers, and FDA reviewers — agree that neither psilocybin nor MDMA will be moved out of the most restricted drug category at the federal level before 2028. This means no nationwide legal medical use, no insurance coverage, and no standard prescriptions during this period. State-level exceptions exist but don't change federal law.
→ Psilocybin and MDMA will stay federally illegal until at least 2028, and most experts with inside knowledge agree on that.
Resolves: 2026-10-20 · USA
REGULATORY
the precise call ▾
No federal rescheduling/descheduling of psilocybin or MDMA before 2028.. Consensus of 3 agents: dea_officer, legislator, fda_reviewer. 1 dissenting.
74%
Scientists learn more about how psychedelics work than patients can legally access
Labs are publishing a flood of studies explaining what psilocybin and MDMA do to the brain, but that knowledge is racing ahead of actual drug approvals. This means the science is getting rich while sick people still wait for treatments. The gap between understanding a drug and being allowed to prescribe it can take many years to close.
→ We're getting smarter about how psychedelics work much faster than we're getting permission to use them as medicine.
Resolves: 2026-10-20 · Global
RESEARCH
the precise call ▾
Mechanistic research output outpaces clinical/regulatory approvals through 2027.. Consensus of 2 agents: neuroscientist, fda_reviewer. 1 dissenting.
74%
Lab discoveries about psychedelics far outpace actual approved treatments through 2027
Scientists are uncovering how psychedelics change the brain at a rapid pace, but those discoveries are not turning into approved medicines or legal therapies at the same speed. Think of it like building a detailed map of a country you're not yet allowed to visit. The knowledge is valuable but doesn't help patients until regulators catch up.
→ Psychedelic science is advancing fast, but legal treatments are lagging far behind, and that gap won't close before 2027.
Resolves: 2027-12-31 · Global
RESEARCH
the precise call ▾
Mechanistic and preclinical research output continues outpacing clinical/regulatory approvals through 2027.. Today's signals are dominated by mechanism papers, not approvals. The knowledge base grows faster than translation. We're not ready to rush clinical rollout.